非何傑金氏淋巴瘤藥物市場規模、佔有率、成長分析（按治療類型、藥物類別、給藥途徑、適應症和地區）—2025 年至 2032 年產業預測

2023 年全球非何傑金氏淋巴瘤藥物市場規模價值 52 億美元，預計將從 2024 年的 55.6 億美元成長到 2032 年的 94.8 億美元，預測期內（2025-2032 年）的複合年成長率為 6.9%。

全球非何傑金氏淋巴瘤(NHL) 藥物市場正在經歷顯著成長，主要原因是人口老化導致 NHL 發病率上升，以及診斷技術的進步使得早期發現成為可能。患者數量的增加導致對有效治療的需求增加，促使製藥公司和醫療保健提供者專注於開發新治療方法。此外，研發投資也大幅增加，推動了市場的擴張。一個顯著的趨勢是免疫療法的進步，特別是嵌合體抗原受體 (CAR) T 細胞療法，它可以有效地瞄準和摧毀癌細胞。這些創新療法改善了患者的治療效果，促進了向個人化治療方案的轉變，進一步推動了非何傑金氏淋巴瘤藥物產業的成長。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

非何傑金氏淋巴瘤藥物市場規模（依治療類型及複合年成長率）（2025-2032）

• 市場概覽
• 化療
• 免疫療法
• 標靶治療
• 放射治療

非何傑金氏淋巴瘤藥物市場規模（依藥物類別及複合年成長率）（2025-2032）

• 市場概覽
• 單株抗體
• 化療藥物
• 布魯頓蛋白酪氨酸激酶抑制劑
• 免疫調節藥物

非何傑金氏淋巴瘤藥物市場規模（依給藥途徑及複合年成長率）（2025-2032）

• 市場概覽
• 靜脈
• 口服
• 皮下

非何傑金氏淋巴瘤藥物市場規模（依適應症和複合年成長率）（2025-2032）

• 市場概覽
• 瀰漫大B細胞淋巴瘤
• 濾泡性淋巴瘤
• 套細胞淋巴瘤
• 套件淋巴瘤

非何傑金氏淋巴瘤藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Roche（Switzerland）
• Novartis（Switzerland）
• Gilead Sciences（USA）
• Bristol-Myers Squibb（USA）
• AbbVie（USA）
• Merck & Co.（USA）
• AstraZeneca（United Kingdom）
• Sanofi（France）
• Bayer AG（Germany）
• Johnson & Johnson（USA）
• Pfizer（USA）
• Eli Lilly and Company（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Genmab（Denmark）
• Seagen Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Kyowa Kirin Co., Ltd.（Japan）
• Spectrum Pharmaceuticals Inc.（USA）
• Autolus Therapeutics（UK）
• Immuneel Therapeutics Private Limited（India）

結論和建議

Global Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 5.2 billion in 2023 and is poised to grow from USD 5.56 billion in 2024 to USD 9.48 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing significant growth, driven by the rising incidence of NHL, primarily due to an aging population and advancements in diagnostic technologies that enable earlier detection. This increasing patient base is resulted in a higher demand for effective treatments, prompting pharmaceutical companies and healthcare providers to focus on developing new therapeutic options. Additionally, there is a surge in research and development investments, stimulating market expansion. A notable trend is the advancement of immunotherapy, particularly Chimeric Antigen Receptor (CAR) T-cell therapies, which effectively target and destroy cancer cells. These innovative treatments improve patient outcomes, fostering a shift toward personalized regimens and further fueling growth within the NHL therapeutics sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Hodgkin Lymphoma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Hodgkin Lymphoma Therapeutics Market Segments Analysis

Global Non-Hodgkin Lymphoma Therapeutics Market is segmented by Therapeutic Type, Drug class, Administration Route, Indication and region. Based on Therapeutic Type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy and Radiation Therapy. Based on Drug class, the market is segmented into Monoclonal Antibodies, Chemotherapeutic Agents, Bruton's Tyrosine Kinase Inhibitors and Immunomodulators. Based on Administration Route, the market is segmented into Intravenous, Oral and Subcutaneous. Based on Indication, the market is segmented into Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma and Burkitt Lymphoma. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Hodgkin Lymphoma Therapeutics Market

The global non-Hodgkin lymphoma therapeutics market is primarily driven by the rising incidence of non-Hodgkin lymphoma, largely attributed to an aging population and various lifestyle factors. As the number of diagnoses continues to climb, there is an escalating need for advanced treatment solutions, including immunotherapies, chemotherapy, and targeted therapies. This heightened demand for innovative treatment options not only reflects the urgency in addressing patients' needs but also propels significant growth in the market, further encouraging research and development efforts aimed at improving patient outcomes and expanding therapeutic possibilities in combating this form of cancer.

Restraints in the Global Non-Hodgkin Lymphoma Therapeutics Market

The growth of the Global Non-Hodgkin Lymphoma Therapeutics market faces substantial obstacles, particularly in developing regions where there is a limited understanding of non-Hodgkin lymphoma. The challenges associated with early diagnosis significantly impede market progression, as insufficient healthcare infrastructure and lack of diagnostic resources create delays in identifying and treating the condition. This lack of timely intervention adversely impacts the demand for therapeutic options, ultimately constraining market expansion in these underserved areas. Addressing these awareness and infrastructure gaps is crucial for enabling better access to treatments and enhancing market potential in the long term.

Market Trends of the Global Non-Hodgkin Lymphoma Therapeutics Market

The Global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing a significant shift towards immunotherapy, particularly with the rise of CAR-T cell therapies. This innovative approach leverages the body's immune response to effectively target and eliminate lymphoma cells, showing remarkable efficacy in patients with relapsed or refractory cases. The increasing approval of these advanced therapies, coupled with ongoing research and clinical trials, underscores a growing acceptance and demand within the healthcare community. As a result, the market is projected to expand rapidly, driven by enhancements in treatment outcomes, patient quality of life, and the potential for personalized medicine strategies in NHL management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Therapeutic Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Drug class & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
• Chemotherapeutic Agents
• Bruton's Tyrosine Kinase Inhibitors
• Immunomodulators

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Administration Route & CAGR (2025-2032)

• Market Overview
• Intravenous
• Oral
• Subcutaneous

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Diffuse Large B-Cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Burkitt Lymphoma

Global Non-Hodgkin Lymphoma Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapeutic Type, Drug class, Administration Route, Indication)
  • US
  • Canada
• Europe (Therapeutic Type, Drug class, Administration Route, Indication)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Type, Drug class, Administration Route, Indication)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Type, Drug class, Administration Route, Indication)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Type, Drug class, Administration Route, Indication)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seagen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immuneel Therapeutics Private Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations